|
|
|
|
| LEADER |
01561nam a2200253 u 4500 |
| 001 |
EB002000554 |
| 003 |
EBX01000000000000001163455 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Jahagirdar, Deepa
|
| 245 |
0 |
0 |
|a Alpha2-adrenergic agonists for the reduction or discontinuation of opioids or opioid substitution therapy
|h Elektronische Ressource
|b a review of clinical effectiveness and guidelines
|c Deepa Jahagirdar and Kaitryn Campbell
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, February 23, 2018
|
| 300 |
|
|
|a 1 PDF file (26 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographic references
|
| 700 |
1 |
|
|a Campbell, Kaitryn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK531931
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Using alpha2-adrenergic agonists may be effective in opioid reduction or discontinuation relative to other supportive interventions or opioid substitution therapies. Further, there may be differences in effectiveness between alpha2-adrenergic agonists in themselves. This review considered the evidence and guidelines to this effect, to explore whether alpha2-adrenergic agonists could assist in reducing the burden of opioid dependence
|